{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:34:16Z","timestamp":1793255656987,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Orphan Disease Center University of Pennsylvania","id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fibrous Dysplasia Foundation","award":["MDBR-19-110-FD"],"award-info":[{"award-number":["MDBR-19-110-FD"]}],"id":[{"id":"https:\/\/ror.org\/025xd2w77","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fibrous Dysplasia Foundation","award":["MDBR-21-110-FD"],"award-info":[{"award-number":["MDBR-21-110-FD"]}],"id":[{"id":"https:\/\/ror.org\/025xd2w77","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fibrous Dysplasia Foundation","award":["MDBR-23-010-FDMAS"],"award-info":[{"award-number":["MDBR-23-010-FDMAS"]}],"id":[{"id":"https:\/\/ror.org\/025xd2w77","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013541","name":"European Calcified Tissue Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013541","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sapienza University","award":["AR223188B3DFA88B"],"award-info":[{"award-number":["AR223188B3DFA88B"]}],"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sapienza University","award":["RP124190960A2E07"],"award-info":[{"award-number":["RP124190960A2E07"]}],"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone fragility and pain are major clinical issues in fibrous dysplasia (FD) of bone, a genetic disorder characterized by increased bone resorption and lytic lesions. Both bisphosphonates (BPs) and denosumab are currently used to treat FD patients, although important concerns remain unsolved. Bisphosphonates downregulate bone remodeling but their effects on FD lesions and pain are variable. Conversely, denosumab converts FD tissue into mineralized bone and prevents disease progression, but disease rebound occurs upon treatment withdrawal. The combination of these 2 drugs may represent an effective and safe strategy for FD treatment. We used a FD mouse model (EF1\u03b1-Gs\u03b1R201C) to assess whether zoledronate (ZOL) addition to anti-RANKL antibody (\u03b1RANKL) treatment could preserve the effects of RANKL inhibition after treatment discontinuation. We show that \u03b1RANKL treatment rapidly reduced bone turnover markers (BTMs) and increased bone mass in affected skeletal segments, but FD lesions recurred shortly after discontinuation. Importantly, \u03b1RANKL+ZOL combination therapy delayed disease rebound after \u03b1RANKL withdrawal, as bone density was preserved, BTM rise was prevented, and no new lesions were observed. Zoledronate monotherapy increased bone density and reduced BTMs but did not fully halt disease progression. Finally, both \u03b1RANKL and \u03b1RANKL+ZOL treatments reduced fracture incidence and improved pain-like behavior in FD mice. These results demonstrate that combining ZOL with denosumab may effectively treat FD. This strategy could particularly benefit patients with severe, rapidly progressive disease, in which RANKL inhibition would block lesion expansion and reduce bone turnover, while ZOL would slow down the resumption of the disease and the rebound effect.<\/jats:p>","DOI":"10.1093\/jbmr\/zjag037","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T12:33:28Z","timestamp":1771763608000},"page":"1249-1264","source":"Crossref","is-referenced-by-count":3,"title":["Effects of anti-RANKL, zoledronate, or combination therapy in a mouse model of fibrous dysplasia: a preclinical study"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-5256","authenticated-orcid":false,"given":"Biagio","family":"Palmisano","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome , 00161 Rome ,","place":["Italy"]},{"name":"Institute for Complex Systems, National Research Council , 00185 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tavanti","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome , 00161 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Farinacci","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome , 00161 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-4509","authenticated-orcid":false,"given":"Alessandro","family":"Corsi","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome , 00161 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Serafini","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori , 20900 Monza ,","place":["Italy"]},{"name":"School of Medicine and Surgery, University of Milano-Bicocca , 20900 Monza ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-127X","authenticated-orcid":false,"given":"Natasha M","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Centre , 2333 Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Riminucci","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome , 00161 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"1","key":"2026102901483369200_ref1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s13023-025-03909-8","article-title":"Fibrous dysplasia\/McCune-Albright syndrome: state-of-the-art advances, pathogenesis, and basic\/translational research","volume":"20","author":"Palmisano","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2026102901483369200_ref2","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/jbmr.3828","article-title":"RANKL inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease","volume":"34","author":"Palmisano","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026102901483369200_ref3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jbmr.3602","article-title":"Activation of RANK\/RANKL\/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden","volume":"34","author":"De Castro","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026102901483369200_ref4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"issue":"9","key":"2026102901483369200_ref5","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2026102901483369200_ref6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"Suppl 1","key":"2026102901483369200_ref7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/1750-1172-7-S1-S3","article-title":"Pathophysiology and medical treatment of pain in fibrous dysplasia of bone","volume":"7","author":"Chapurlat","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2026102901483369200_ref8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and efficacy of denosumab for fibrous dysplasia of bone","volume":"388","author":"De Castro","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102901483369200_ref9","doi-asserted-by":"publisher","first-page":"116301","DOI":"10.1016\/j.bone.2021.116301","article-title":"RANKL inhibition halts lesion progression and promotes bone remineralization in mice with fibrous dysplasia","volume":"156","author":"Liu","year":"2022","journal-title":"Bone"},{"key":"2026102901483369200_ref10","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.26.672317","article-title":"Exploring the mechanism and pattern of bone formation during RANKL inhibition in a mouse model of fibrous dysplasia","author":"Farinacci","year":"2025","journal-title":"bioRxiv"},{"issue":"7","key":"2026102901483369200_ref11","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026102901483369200_ref12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026102901483369200_ref13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026102901483369200_ref14","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2026102901483369200_ref15","doi-asserted-by":"publisher","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","article-title":"The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"138","author":"Makras","year":"2020","journal-title":"Bone"},{"issue":"6","key":"2026102901483369200_ref16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00223-020-00752-w","article-title":"Zoledronic acid in a mouse model of human fibrous dysplasia: ineffectiveness on tissue pathology, formation of \u2018Giant osteoclasts\u2019 and pathogenetic implications","volume":"107","author":"Corsi","year":"2020","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2026102901483369200_ref17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/jbmr\/zjaf066","article-title":"Bone pain in fibrous dysplasia does not rely on aberrant sensory nerve sprouting or neuroma formation","volume":"40","author":"Palmisano","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026102901483369200_ref18","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1002\/jbmr.2267","article-title":"Constitutive expression of Gs\u03b1(R201C) in mice produces a heritable, direct replica of human fibrous dysplasia bone pathology and demonstrates its natural history","volume":"29","author":"Saggio","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"S2","key":"2026102901483369200_ref19","doi-asserted-by":"publisher","first-page":"P114","DOI":"10.1359\/jbmr.06s222","article-title":"Medical therapy in adults with fibrous dysplasia of bone","volume":"21","author":"Chapurlat","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026102901483369200_ref20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"1","key":"2026102901483369200_ref21","doi-asserted-by":"publisher","first-page":"012","DOI":"10.29328\/journal.johcs.1001002","article-title":"Evaluation of ImageJ for relative bone density measurement and clinical application","volume":"1","author":"Geiger","year":"2016","journal-title":"J Oral Health Craniofac Sci"},{"issue":"1","key":"2026102901483369200_ref22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41413-022-00220-1","article-title":"Gs\u03b1R201C and estrogen reveal different subsets of bone marrow adiponectin expressing osteogenic cells","volume":"10","author":"Palmisano","year":"2022","journal-title":"Bone Res"},{"key":"2026102901483369200_ref23","doi-asserted-by":"publisher","first-page":"117047","DOI":"10.1016\/j.bone.2024.117047","article-title":"A pathogenic role for brain-derived neurotrophic factor (BDNF) in fibrous dysplasia of bone","volume":"181","author":"Palmisano","year":"2024","journal-title":"Bone"},{"issue":"1","key":"2026102901483369200_ref24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026102901483369200_ref25","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1172\/JCI125915","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"129","author":"Bonnet","year":"2019","journal-title":"J Clin Invest"},{"issue":"9","key":"2026102901483369200_ref26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/jbmr\/zjaf037","article-title":"Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures","volume":"40","author":"Kumar","year":"2025","journal-title":"J Bone Miner Res"},{"key":"2026102901483369200_ref27","doi-asserted-by":"publisher","first-page":"101148","DOI":"10.1016\/j.bonr.2021.101148","article-title":"Hypercalcemia following discontinuation of denosumab therapy: a systematic review","volume":"15","author":"Horiuchi","year":"2021","journal-title":"Bone Rep"},{"issue":"1","key":"2026102901483369200_ref28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026102901483369200_ref29","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.bone.2007.12.225","article-title":"Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells","volume":"42","author":"Coxon","year":"2008","journal-title":"Bone"},{"key":"2026102901483369200_ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.582316","article-title":"Response to zoledronic acid infusion in children with fibrous dysplasia","volume":"8","author":"Tripathy","year":"2020","journal-title":"Front Pediatr"},{"issue":"8","key":"2026102901483369200_ref31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"2026102901483369200_ref32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jbmr.4463","article-title":"Long bone fractures in fibrous dysplasia\/McCune-Albright syndrome: prevalence, natural history, and risk factors","volume":"37","author":"Geels","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2026102901483369200_ref33","doi-asserted-by":"publisher","first-page":"115784","DOI":"10.1016\/j.bone.2020.115784","article-title":"Bisphosphonates for the treatment of fibrous dysplasia of bone","volume":"143","author":"Chapurlat","year":"2021","journal-title":"Bone"},{"issue":"3","key":"2026102901483369200_ref34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom"},{"issue":"2","key":"2026102901483369200_ref35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.20945\/2359-3997000000459","article-title":"Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience","volume":"66","author":"Valadares","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"2026102901483369200_ref36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","article-title":"Men and mice: relating their ages","volume":"152","author":"Dutta","year":"2016","journal-title":"Life Sci"},{"key":"2026102901483369200_ref37","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.106.026","article-title":"Hypercalcemia following discontinuation of denosumab in adults: a case report","volume":"106","author":"Tondeur","year":"2024","journal-title":"Endocr Abstr"},{"issue":"5","key":"2026102901483369200_ref38","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad133","article-title":"Denosumab-induced rebound hypercalcemia treated with bisphosphonates in a pediatric patient","volume":"1","author":"Gandolfi","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"1","key":"2026102901483369200_ref39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"2026102901483369200_ref40","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026102901483369200_ref41","doi-asserted-by":"publisher","first-page":"101058","DOI":"10.1016\/j.bonr.2021.101058","article-title":"Regression of fibrous dysplasia in response to denosumab therapy: a report of two cases","volume":"14","author":"Meier","year":"2021","journal-title":"Bone Rep"},{"issue":"2","key":"2026102901483369200_ref42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jos.2016.11.017","article-title":"Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures","volume":"22","author":"Tetsunaga","year":"2017","journal-title":"J Orthop Sci"},{"issue":"3","key":"2026102901483369200_ref43","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.3390\/ijms24032550","article-title":"Pharmacological interventions targeting pain in fibrous dysplasia\/McCune\u2013Albright syndrome","volume":"24","author":"Tucker-Bartley","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026102901483369200_ref44","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026102901483369200_ref45","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026102901483369200_ref46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jbmr\/zjaf039","article-title":"Pain in fibrous dysplasia: identifying nociceptive mechanisms in a preclinical model","volume":"40","author":"Hopkins","year":"2025","journal-title":"J Bone Miner Res"},{"key":"2026102901483369200_ref47","doi-asserted-by":"publisher","first-page":"117552","DOI":"10.1016\/j.bone.2025.117552","article-title":"Impact of denosumab on muscle health in older adults in long-term care","volume":"198","author":"Haeri","year":"2025","journal-title":"Bone"},{"key":"2026102901483369200_ref48","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.01.543305","article-title":"Zoledronic acid improves bone quality and muscle function in a high bone turnover state","author":"Trivedi","year":"2023","journal-title":"bioRxiv"},{"issue":"4","key":"2026102901483369200_ref49","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.1999.01774.x","article-title":"A time kinetic study of the effect of aminobisphosphonate on murine haemopoiesis","volume":"107","author":"Nakamura","year":"1999","journal-title":"Br J Haematol"},{"issue":"1","key":"2026102901483369200_ref50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1600-0773.1988.tb01843.x","article-title":"A one year follow-up study of the distribution of 14C-clodronate in mice and rats","volume":"62","author":"M\u00f6nkk\u00f6nen","year":"1988","journal-title":"Pharmacol Toxicol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag037\/67087853\/zjag037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/11\/1249\/67087853\/zjag037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/11\/1249\/67087853\/zjag037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:48:39Z","timestamp":1793252919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/11\/1249\/8495781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,2,24]]},"published-print":{"date-parts":[[2026,10,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjag037","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.09.08.672330","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,2,24]]}}}